An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...
A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...
Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised ...
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, Norway, and North Macedonia. Read more here.
The U.S. Department of Health and Human Services announced it will award $590 million to Moderna to accelerate the development of influenza vaccines, including to protect against bird flu.